Novartis Backs Medical Test Patent In High Court

Law360, New York (November 14, 2011, 4:36 PM EST) -- Novartis Corp. has thrown its support behind Prometheus Laboratories Inc. in its upcoming U.S. Supreme Court showdown with Mayo Collaborative Services over the patentability of a Prometheus blood testing method, Novartis counsel Baker Botts LLP said last week.

Novartis argued Wednesday in a brief with the high court that Prometheus’ patent on its drug dosage test method must stand, as the patent does not seek to monopolize natural biological relationships.

Invalidation of the patent “would have a chilling effect on the advancement of the health care...
To view the full article, register now.